May 12 (UPI) -- Polycystic ovary syndrome, known to more than 170 million women suffering from the condition worldwide, was renamed polyendocrine metabolic ovarian syndrome Tuesday by patients and medical organizations.
PMOS causes fluctuations in hormones, with impacts on weight, metabolic and mental health, skin and the reproductive system.
"For too long, the name reduced a complex, long-term hormonal or endocrine disorder to a misunderstanding about 'cysts' and a focus on ovaries. This contributed to missed diagnoses and inadequate treatment," a press release from the Endocrine Society said.
Professor Helena Teede, director of Monash University's Monash Centre for Health Research & Implementation and an endocrinologist at Monash Health in Melbourne, Australia, led the name change process after spending decades researching the condition and seeing the patient impacts firsthand, the release said.
"What we now know is that there is actually no increase in abnormal cysts on the ovary, and the diverse features of the condition were often unappreciated," Teede said in a statement. "It was heart-breaking to see the delayed diagnosis, limited awareness and inadequate care afforded those affected by this neglected condition.
